Crossmark

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation

Crossref DOI link: https://doi.org/10.1016/j.medcle.2021.01.004

Published Print: 2021-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aomar-Millán, Ismael Francisco

Salvatierra, Juan

Torres-Parejo, Úrsula

Nuñez-Nuñez, María

Hernández-Quero, José

Anguita-Santos, Francisco
License Information

Text and Data Mining valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01
More Information

This article is maintained by: Elsevier

Article Title: Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2021.01.004

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2021.01.006

Content Type: simple-article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.